226 related articles for article (PubMed ID: 36108790)
21. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
23. DOUBLE RETINAL PIGMENT EPITHELIUM TEARS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Mouallem A; Sarraf D; Chen X; Capuano V; Souied EH; Querques G
Retina; 2016 Nov; 36(11):2197-2204. PubMed ID: 27145251
[TBL] [Abstract][Full Text] [Related]
24. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
[TBL] [Abstract][Full Text] [Related]
25. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
26. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
27. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
[TBL] [Abstract][Full Text] [Related]
28. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
29. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration.
Kim M; Kim ES; Seo KH; Yu SY; Kwak HW
Indian J Ophthalmol; 2016 Jun; 64(6):427-33. PubMed ID: 27488150
[TBL] [Abstract][Full Text] [Related]
30. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
Prahs P; Brandl C; Helbig H; Volz C
Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
[No Abstract] [Full Text] [Related]
31. Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT.
Toth CA; Tai V; Pistilli M; Chiu SJ; Winter KP; Daniel E; Grunwald JE; Jaffe GJ; Martin DF; Ying GS; Farsiu S; Maguire MG;
Ophthalmol Retina; 2019 Apr; 3(4):316-325. PubMed ID: 31014683
[TBL] [Abstract][Full Text] [Related]
32. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
33. Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors.
Oliveira MA; Farinha C; Rodrigues TM; Martins A; Cachulo MDL; Marques JP; Pires I; Silva R
Eur J Ophthalmol; 2021 Mar; 31(2):521-528. PubMed ID: 32103681
[TBL] [Abstract][Full Text] [Related]
34. Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients.
Kim KT; Chae JB; Lee S; Seo EJ; Kim DY
BMC Ophthalmol; 2021 Aug; 21(1):294. PubMed ID: 34376158
[TBL] [Abstract][Full Text] [Related]
35. Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration.
Beck M; Munk MR; Ebneter A; Wolf S; Zinkernagel MS
Am J Ophthalmol; 2016 Jul; 167():10-7. PubMed ID: 27084000
[TBL] [Abstract][Full Text] [Related]
36. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy.
Fang M; Chanwimol K; Maram J; Datoo O'Keefe GA; Wykoff CC; Sarraf D; Brown A; Lampen SIR; Zhou B; Rusakevich AM; Sadda S
Br J Ophthalmol; 2023 Mar; 107(3):399-405. PubMed ID: 34561217
[TBL] [Abstract][Full Text] [Related]
37. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
38. Progression of Macular Atrophy in Patients Receiving Long-Term Anti-VEGF Therapy for Age-Related Macular Degeneration: Real-Life Data.
Blazaki S; Blavakis E; Smoustopoulos G; Bontzos G; Stavrakakis A; Chlouverakis G; Kabanarou S; Xirou T; Tsilimbaris M
Ophthalmologica; 2022; 245(2):152-160. PubMed ID: 34818657
[TBL] [Abstract][Full Text] [Related]
39. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.
Chandra S; Arpa C; Menon D; Khalid H; Hamilton R; Nicholson L; Pal B; Fasolo S; Hykin P; Keane PA; Sivaprasad S
Eye (Lond); 2020 Oct; 34(10):1888-1896. PubMed ID: 31980748
[TBL] [Abstract][Full Text] [Related]
40. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
